Gaucher type 1 concentrates in the Ashkenazi Jewish founder population at 1 in 500-1,000, and the same genotype carries a near 20-fold Parkinson's risk.

Gaucher disease is an autosomal-recessive lysosomal storage disorder caused by biallelic mutations in GBA1, producing deficient acid beta-glucosidase and a buildup of glucosylceramide in macrophages that infiltrate spleen, liver and bone marrow. Disease divides into three types by neurological involvement: type 1, non-neuronopathic, accounts for more than 90% of patients, while types 2 and 3, far rarer, involve progressive central nervous system degeneration. Type 1 presents with splenomegaly, an enlarged liver, anaemia, low platelets and skeletal disease, not the CNS decline that defines the other two types.

Genotype predicts phenotype. The N370S variant, present on at least one allele, protects against neuronopathic disease and defines type 1; the L444P variant in the homozygous state is linked to the neuronopathic forms. Type 1 is markedly enriched in the Ashkenazi Jewish population, where carrier frequency runs about 1 in 12 to 15 and disease frequency roughly 1 in 500 to 1,000, versus 0.70 to 1.75 per 100,000 in the general population. Many 'asymptomatic' N370S homozygotes in fact have measurable anaemia or an enlarged spleen on evaluation. GBA1 is also the single most common genetic risk factor for Parkinson's disease, and diagnosed type 1 patients carry a lifetime risk ratio of 21.4.

The genotype that protects against neuronopathic Gaucher also predicts Parkinson's risk.

Five questions this report answers:

Q1 - How does the Ashkenazi Jewish founder effect concentrate US Gaucher prevalence?

Q2 - How does GBA1 genotype predict the type 1, 2 and 3 split?

Q3 - Where does the GBA1-Parkinson's link create screening opportunity?

Q4 - How common is Gaucher disease type 1 in the US?

Q5 - How do N370S and L444P variants differ in disease outcome?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#GaucherDisease #GBA1 #RareDisease #LysosomalStorageDisorder #AshkenaziJewish #USHealthcare

Live report page:  https://axlrx.ai/gaucher-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/